Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PALbociclib in Advanced Breast Cancer: Therapy INtegrating locorEgional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

NCT03870919 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03870919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03870919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PALbociclib in Advanced Breast Cancer: Therapy INtegrating locorEgional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
Lead sponsor
UNICANCER
Phase
Not applicable
Overall status
Active, not recruiting
Start date
October 23, 2019
Completion date
October 23, 2027
Enrollment
200 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage iv, radiotherapy, surgery